Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online November 26, 2007
Diabetes Care 31:397-401, 2008
DOI: 10.2337/dc07-1898
© 2008 by the American Diabetes Association
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-1898v1
31/3/397    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fukui, M.
Right arrow Articles by Nakamura, N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fukui, M.
Right arrow Articles by Nakamura, N.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Clinical Care/Education/Nutrition/Psychosocial Research
Original Research

Association Between Serum Bioavailable Testosterone Concentration and the Ratio of Glycated Albumin to Glycated Hemoglobin in Men With Type 2 Diabetes

Michiaki Fukui, MD1, Muhei Tanaka, MD1, Goji Hasegawa, MD1, Toshikazu Yoshikawa, MD2 and Naoto Nakamura, MD1

1 Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
2 Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Address correspondence and reprint requests to Michiaki Fukui, MD, Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. E-mail: sayarinapm{at}hotmail.com


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESEARCH DESIGN AND METHODS--
 RESULTS--
 CONCLUSIONS--
 References
 
OBJECTIVE—Testosterone stimulates erythropoiesis and thus glycated hemoglobin (A1C) values may be relatively low in male diabetic patients with hypogonadism. We therefore investigated relationships between serum bioavailable testosterone concentration and the ratio of glycated albumin (GA) to A1C and between serum bioavailable testosterone and hemoglobin concentrations in men with type 2 diabetes.

RESEARCH DESIGN AND METHODS—The above relationships were investigated in 222 consecutive men with type 2 diabetes. We also investigated how the ratio of GA to A1C is related to other variables such as age, BMI, and degree of diabetic microangiopathy.

RESULTS—Mean ratio of GA to A1C was 2.94 ± 0.38. Serum bioavailable testosterone concentration correlated positively with hemoglobin concentration (r = 0.368, P < 0.0001) and negatively with the ratio of GA to A1C (r = –0.278, P < 0.0001). Multiple regression analyses identified serum bioavailable testosterone concentration (β = 0.187, P = 0.0062), age (β = –0.204, P = 0.0075), BMI (β = 0.151, P = 0.0302), systolic blood pressure (β = 0.173, P = 0.0090), and plasma total cholesterol (β = 0.155, P = 0.0141) as independent determinants of hemoglobin concentration; moreover, serum bioavailable testosterone concentration (β = –0.155, P = 0.0381) and plasma total cholesterol (β = –0.170, P = 0.0144) were identified as independent determinants of the ratio of GA to A1C.

CONCLUSIONS—Serum bioavailable testosterone concentration correlated positively with hemoglobin concentration and negatively with the ratio of GA to A1C in men with type 2 diabetes, which may lead to underestimation of A1C in hypogonadal men with type 2 diabetes.

Abbreviations: CVD, cardiovascular disease • GA, glycated albumin


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESEARCH DESIGN AND METHODS--
 RESULTS--
 CONCLUSIONS--
 References
 
Testosterone stimulates erythropoiesis, while testosterone replacement therapy increases hemoglobin concentration (1,2). One might suspect that declining serum testosterone concentrations during aging could compromise erythropoiesis. Accordingly, men with hypogonadism and those treated with antiandrogenic drugs frequently have anemia (3,4). Since the influence of serum bioavailable testosterone on hemoglobin concentration has not been investigated in men with type 2 diabetes, we presently examined this relationship and its possible implications for management of diabetes.

Measurements of glycated hemoglobin (A1C) and glycated albumin (GA) have been used clinically to monitor glycemic control in patients with diabetes. A1C represents an integrated measurement of blood glucose during the preceding 2 months while serum GA, a shorter-term marker, reflects glycemic control over approximately the preceding 2 weeks (5–7). GA is not influenced by a number of physiologic and pathologic conditions that affect A1C levels, such as anemia and genetic hemoglobin abnormalities (8,9).

The considerations above raise the possibility that A1C levels might be relatively low in male diabetic patients with hypogonadism. To our knowledge, relationships between serum endogenous androgens and the GA-to-A1C ratio have not been explored in men with type 2 diabetes. We therefore investigated the effect of serum bioavailable testosterone concentration on GA-to-A1C ratio in these patients.


   RESEARCH DESIGN AND METHODS—
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
RESULTS--
 CONCLUSIONS--
 References
 
Serum bioavailable testosterone concentrations were measured in 222 consecutive men with type 2 diabetes recruited from the outpatient clinic at the Kyoto Prefectural University of Medicine. Relationships between serum bioavailable testosterone and hemoglobin concentrations and between serum bioavailable testosterone concentration and GA-to-A1C ratio were investigated. In addition, we evaluated relationships between GA-to-A1C ratio and age, duration of diabetes, blood pressure, plasma lipid concentration, BMI, waist circumference, severity of diabetic retinopathy, severity of diabetic nephropathy defined by urinary albumin excretion, presence of cardiovascular disease (CVD), smoking status, and current treatment for diabetes.

Blood samples were obtained in the morning. Bioavailable testosterone was separated using precipitation of testosterone bound to globulins with 50% ammonium sulfate, and serum bioavailable testosterone concentrations were measured by the liquid chromatography–tandem mass spectrometry using a modification method based on the use of picolinoyl derivatization (10). Intra-assay and interassay coefficients of variation (CVs) for serum bioavailable testosterone concentrations at 1 pg/ml were 4.73 and 12.94%, respectively. Hemoglobin concentrations were analyzed within 4 h of blood drawing using a SYSMEX XE-2100 autoanalyzer (Sysmex Corporation, Kobe, Japan). A1C was measured by high-performance liquid chromatography using an ADAMS-A1c HA-8160 (Arkray, Kyoto, Japan). Interassay CVs determined using representative blood samples with 5.2 and 10.9% A1C were 0.63 and 0.45%, respectively. GA was determined by an enzymatic method using albumin-specific proteinase, ketoamine oxidase, and an albumin assay reagent (Lucica GA-L; Asahi Kasei Pharma, Tokyo, Japan), with a Hitachi 7600 autoanalyzer (Hitachi Instrument Service, Tokyo, Japan). Interassay CVs determined using representative serum samples with 17.2 and 26.9% GA were 1.08 and 1.37%, respectively. Plasma total cholesterol, HDL cholesterol, and triglyceride concentrations were assessed using standard enzymatic methods. Mean values for biochemical parameters obtained during the preceding year were used for statistical analysis. Urinary albumin and creatinine concentration was determined in early morning spot urine. Urinary albumin excretion was measured with an immunoturbidimetric assay. A mean value for urinary albumin excretion was determined from three urine collections.

Type 2 diabetes was diagnosed according to the Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (11). Retinopathy was graded as no diabetic retinopathy, simple diabetic retinopathy, or proliferative diabetic retinopathy. Nephropathy was graded as normoalbuminuria (urinary albumin excretion <30 mg/g creatinine) or microalbuminuria (30–300 mg/g creatinine). Sitting blood pressure was measured after a 5-min rest. CVD was defined as a previous myocardial or cerebral infarction based on the clinical history or physical examination. Subjects were classified as nonsmokers, past smokers, or current smokers according to a self-administered questionnaire. Patients were excluded if they had undergone castration for treatment of testicular or prostate cancer or were taking any medications known to affect sex hormone concentrations (e.g., antiandrogenic agents for prostate cancer). In addition, patients with macroalbuminuria were excluded since advanced diabetic nephropathy can influence hemoglobin concentration. Moreover, patients with malignant disease, liver cirrhosis, thyroid disorders, hematologic disease, or infectious disease were excluded from this study. To minimize effects of diabetes treatment on time-dependent variations of A1C and GA levels, we selected patients whose A1C levels had been stable for at least the preceding 3 months. Approval for the study was obtained from the local research ethics committee, and informed consent was obtained from all participants.

Statistical analysis
Means or frequencies of potential confounding variables were calculated as appropriate. Unpaired Student's t tests or ANOVAs were conducted to assess statistical significance of differences between groups using Stat View software (version 5.0; SAS Institute, Cary, NC). Because plasma triglyceride concentration showed a skewed distribution, logarithmic (log) transformation was carried out before performing a correlation analysis. Correlations between serum bioavailable testosterone concentration and hemoglobin concentration or GA-to-A1C ratio, as well as between GA-to-A1C ratio and age, duration of diabetes, BMI, or other variables, were examined by Pearson's correlation analyses. All continuous variables are presented as means ± SD. Multiple linear regression analysis was performed to assess the combined influence of variables on hemoglobin concentration or GA-to-A1C ratio. To examine the effects of various factors on hemoglobin concentration or GA-to-A1C ratio, the following factors were considered independent variables: serum bioavailable testosterone concentration, age, duration of diabetes, BMI, systolic blood pressure, plasma total cholesterol concentration, and smoking status. A P value <0.05 was considered statistically significant.


   RESULTS—
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
 RESULTS--
CONCLUSIONS--
 References
 
Characteristics of the 222 men with type 2 diabetes enrolled in this study are shown in Table 1. Mean GA-to-A1C ratio was 2.94 ± 0.38.


View this table:
[in this window]
[in a new window]

  		Table 1— Clinical characteristics of patients with diabetes

 
Relationships between GA-to-A1C ratio and other variables are shown in Table 2. Age, duration of diabetes, and plasma HDL cholesterol concentration were positively associated with GA-to-A1C ratio, while BMI, waist circumference, systolic blood pressure, diastolic blood pressure, plasma total cholesterol concentration, and log(plasma triglyceride concentration) were negatively associated with GA-to-A1C ratio. A positive correlation was found between serum bioavailable testosterone and hemoglobin concentrations (r = 0.368, P < 0.0001 (Fig. 1A), while a negative correlation was found between serum bioavailable testosterone concentration and GA-to-A1C ratio (r = –0.278, P < 0.0001) (Fig. 1B). No significant correlation was found between serum bioavailable testosterone and albumin concentrations (r = 0.147, P = 0.0625). Multiple regression analyses identified serum bioavailable testosterone concentration (β = 0.187, P = 0.0062), age (β = –0.204, P = 0.0075), BMI (β = 0.151, P = 0.0302), systolic blood pressure (β = 0.173, P = 0.0090), and plasma total cholesterol (β = 0.155, P = 0.0141) as independent determinants of hemoglobin concentration; moreover, serum bioavailable testosterone concentration (β = –0.155, P = 0.0381) and plasma total cholesterol (β = –0.170, P = 0.0144) were identified as independent determinants of GA-to-A1C ratio (Table 3).


View this table:
[in this window]
[in a new window]

  		Table 2— Correlation between GA-to-A1C ratio and other variables

 

Figure 1
View larger version (11K):
[in this window]
[in a new window]

  		Figure 1— Correlations between serum bioavailable testosterone and hemoglobin concentrations (A) and between serum bioavailable testosterone concentration and GA-to-A1C ratio (B) in men with type 2 diabetes.

 

View this table:
[in this window]
[in a new window]

  		Table 3— Multiple regression analysis on hemoglobin concentration or GA-to-A1C ratio

 
GA-to-A1C ratio did not differ between patients with normoalbuminuria and microalbuminuria (2.94 ± 0.40 vs. 2.97 ± 0.35, P = 0.5162). GA-to-A1C ratio was higher in patients with proliferative diabetic retinopathy (3.16 ± 0.25, P = 0.0128) or simple diabetic retinopathy (3.10 ± 0.28, P = 0.0142) than that in patients without diabetic retinopathy (2.91 ± 0.40). GA-to-A1C ratio did not differ between patients with or without CVD (2.97 ± 0.37 vs. 2.95 ± 0.38, P = 0.7238). GA-to-A1C ratio was higher in patients treated with than without insulin (3.15 ± 0.45 vs. 2.87 ± 0.32, P < 0.0001). GA-to-A1C ratio did not differ between patients treated with or without statin (2.88 ± 0.37 vs. 2.96 ± 0.38, P = 0.1821), angiotensin II receptor blocker, or ACE inhibitor (2.95 ± 0.36 vs. 2.94 ± 0.39, P = 0.7533). GA-to-A1C ratio was higher in patients treated with than without antiplatelet agent (3.05 ± 0.46 vs. 2.92 ± 0.35, P = 0.0416). GA-to-A1C ratio did not differ according to smoking status (2.90 ± 0.27, 2.93 ± 0.41, and 3.04 ± 0.46 for current smokers, past smokers, and nonsmokers, respectively).


   CONCLUSIONS—
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
 RESULTS--
 CONCLUSIONS--
References
 
Serum bioavailable testosterone concentration correlated positively with hemoglobin concentration in men with type 2 diabetes, which is compatible with previous findings in the general population. Serum bioavailable testosterone concentration correlated negatively with GA-to-A1C ratio. Multiple regression analysis also identified serum bioavailable testosterone as a determinant of hemoglobin concentration or GA-to-A1C ratio.

GA and A1C have a tendency to vary in parallel, although the normal range of variation of GA-to-A1C ratio has not yet been determined. GA and A1C are equivalent measures of glycemic control in general, although the former is a short-term and the latter a long-term marker. In certain diabetic patients in whom A1C measurement proves insufficient for clinical management (8,9), measurement of serum GA represents an alternative assessment of glycemic control. For example, anemia is an important factor affecting A1C levels. Thus, changes in the GA-to-A1C ratio would indicate artifactual change, which lends GA-to-A1C ratio clinical value.

Our results suggest that we may underestimate A1C level in male diabetic patients with hypogonadism because of a negative association between serum bioavailable testosterone concentration and GA-to-A1C ratio that arises partly from a positive association between serum bioavailable testosterone and hemoglobin concentrations. Men with diabetes have significantly lower plasma concentrations of endogenous androgen than nondiabetic men (12–15); endogenous androgen concentrations also decline with advancing age (16). Close attention should be paid to diabetic men with poor diabetes control or advanced age with regard to evaluation of A1C levels.

GA-to-A1C ratio was negatively associated with BMI or waist circumference in the present study. Koga et al. (17) made a similar observation, suggesting that increased serum albumin turnover in obese subjects could keep serum GA low relative to plasma glucose concentrations. We additionally found age to be positively associated with GA-to-A1C ratio and systolic blood pressure or plasma total cholesterol concentration to be negatively associated with GA-to-A1C ratio. Although the reasons for these associations are not clear, possible explanations may be that age (r = –0.390, P < 0.0001) is negatively associated with hemoglobin while systolic blood pressure (r = 0.253, P = 0.0002) or plasma total cholesterol concentration (r = 0.258, P = 0.0001) is positively associated with hemoglobin concentration. Cholesterol is a precursor of testosterone, and serum bioavailable testosterone concentration is positively associated with plasma total cholesterol concentration (r = 0.194, P = 0.0039). GA-to-A1C ratio was higher according to progression of diabetic retinopathy. Finally, ongoing treatment for diabetic patients such as insulin or antiplatelet agent was associated with GA-to-A1C ratio.

We excluded patients with macroalbuminuria in this study because advanced diabetic nephropathy can influence hemoglobin concentration. MacIsaac RJ et al. (18) demonstrated that patients with type 2 diabetes can progress to a significant degree of renal impairment while remaining normoalbuminuric. Certainly, estimated glomerular filtration rates were below 60 ml/min per 1.73 m2 in 42 of 222 patients in this study. However, a significant correlation between serum bioavailable testosterone and hemoglobin concentrations (r = 0.343, P < 0.0001) or between serum bioavailable testosterone concentration and GA-to-A1C ratio (r = –0.292, P < 0.0001) persisted even after excluding patients with estimated glomerular filtration rate <60 ml/min per 1.73 m2.

That we could not have control groups of nondiabetic men with and without hypogonadism and/or hypogonadal men before and after testosterone replacement constitutes a limitation to our study, as we cannot see whether GA-to-A1C ratio is different and varies in these populations.

To our knowledge, this is the first study to investigate the relationship between serum bioavailable testosterone concentration and GA-to-A1C ratio and the relationship between serum bioavailable testosterone and hemoglobin concentrations in men with type 2 diabetes. The results of this study have raised new issues concerning the pathophysiologic characteristics of anemia in male diabetic patients with hypogonadism. The mechanism through which testosterone stimulates erythropoiesis is unclear. Testosterone enhances proliferation of erythroid burst-forming units and colony-forming units by stimulating specific nuclear receptors (19). Medras et al. (20) demonstrated the significant decrease of aldolase and pyruvate kinase activity in erythrocytes in men with hypogonadism, which may decrease the lifespan of erythrocyte. Moreover, Solomon et al. (21) reported that androgen therapy prolongs red cell survival and increases red cell production. We suggest that low serum bioavailable testosterone concentration could be an underrecognized contributor to anemia, while a low serum bioavailable testosterone concentration could affect GA-to-A1C ratio and thus cause spuriously low A1C values. Our findings should be confirmed in larger populations and in other clinical settings before they can be considered for clinical applications.

In conclusion, serum bioavailable testosterone concentration correlated positively with hemoglobin concentration and negatively with GA-to-A1C ratio in men with type 2 diabetes, which may lead to underestimation of A1C in hypogonadal men with type 2 diabetes, although in this study we cannot clarify whether these findings are applicable to nondiabetic men.


   Footnotes
 
Published ahead of print at http://care.diabetesjournals.org on 26 November 2007. DOI: 10.2337/dc07-1898.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

Received for publication September 29, 2007. Accepted for publication November 15, 2007.


   References
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS--
 RESULTS--
 CONCLUSIONS--
 References
 

  1. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Maqliano L, Storer TW: Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90:678–688, 2005[Abstract/Free Full Text]
  2. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow DA, Holmes JH, Kapoor SC, Atkinson LE, Strom BL: Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85:2670–2677, 2000[Abstract/Free Full Text]
  3. Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, Valenti G, Ershler WB, Guralnik JM, Longo DL: Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 166:1380–1388, 2006[Abstract/Free Full Text]
  4. Fonseca R, Rajkumar SV, White WL, Tefferl A, Hoagland HC: Anemia after orchiectomy. Am J hematol 59:230–233, 1998[Medline]
  5. Guthrow CE, Morris MA, Day JF, Thorpe SR, Baynes JW: Enhanced nonenzymatic glucosylation of human serum albumin in diabetes mellitus. Proc Natl Acad Sci U S A 76:4258–4261, 1979[Abstract/Free Full Text]
  6. Shima K, Ito N, Abe F, Hirota M, Yano M, Yamamoto Y, Uchida T, Noguchi K: High-performance liquid chromatographic assay of serum glycated albumin. Diabetologia 31:627–631, 1988[Medline]
  7. Olufemi S, Talwar D, Robb DA: The relative extent of glycation of haemoglobin and albumin. Clin Chim Acta 163:125–136, 1987[Medline]
  8. Jeffcoate SL: Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 21:657–665, 2004[Medline]
  9. Bry L, Chen PC, Sacks DB: Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 47:153–163, 2001[Abstract/Free Full Text]
  10. Yamashita K, Okuyama M, Watanabe Y, Honma S, Kobayashi S, Numazawa M: Highly sensitive determination of estrone and estradiol in human serum by liquid chromatography-electrospray ionization tandem mass spectrometry. Steroids 72:819–827, 2007[Medline]
  11. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 25(Suppl. 1):S5–S20, 2002
  12. Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P: Testosterone concentrations in women and men with NIDDM. Diabetes Care 17:405–411, 1994[Abstract]
  13. Barrett-Connor E: Lower endogenous androgen levels and dyslipidaemia in men with NIDDM. Ann Intern Med 117:807–811, 1992[Medline]
  14. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH: Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30:911–917, 2007[Abstract/Free Full Text]
  15. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, Dobs A, Basaria S, Golden SH, Platz EA: Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 30:234–238, 2007[Abstract/Free Full Text]
  16. Blouin K, Despres J-P, Couillard C, Tremblay A, Prudhomme D, Bouchard C, Tchernof A: Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 54:1034–1040, 2005[Medline]
  17. Koga M, Matsumoto S, Saito H, Kasayama S: Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J 53:387–391, 2006[Medline]
  18. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G: Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27:195–200, 2004[Abstract/Free Full Text]
  19. Malgor LA, Valsecia M, Verges E, Markowsky EE: Blockade of the in vitro effects of testosterone and erythropoietin on CFU-E and BFU-E proliferation by pretreatment of the donor rats with cyproterone and flutamide. Acta Physiol Pharmacol Ther Latinoam 48:99–105, 1998[Medline]
  20. Medras M, Checinska E, Silber-Kasprzak D, Gwozdz K: Decrease of aldolase and pyruvate kinase activity in erythrocytes of individuals with male hypogonadism as an expression of lack of androgen influence on the bone marrow. Andrologia 15:44–49, 1983[Medline]
  21. Solomon LR, Hendler ED: Androgen therapy in haemodialysis patients. II. Effects on red cell metabolism. Br J Haematol 65:223–230, 1987[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-1898v1
31/3/397    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fukui, M.
Right arrow Articles by Nakamura, N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fukui, M.
Right arrow Articles by Nakamura, N.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum